Related Experiment Video
Updated: Jan 9, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Efficacy of Oscillation-Induced Depolymerization for Pseudothrombocytopenia Management Under Varying Conditions
Oscillation at 3,000 rpm for 3 minutes effectively mitigates pseudothrombocytopenia (PTCP) by depolymerizing platelets. This method significantly improves platelet counts and offers a promising clinical solution for PTCP management.
Area of Science:
- Hematology
- Biophysics
Background:
- Pseudothrombocytopenia (PTCP) is a pre-analytical condition that can lead to misdiagnosis.
- Platelet (PLT) clumping in vitro necessitates effective depolymerization strategies.
Purpose of the Study:
- To evaluate the efficacy of oscillation-induced depolymerization in managing PTCP.
- To determine optimal oscillatory conditions for platelet depolymerization.
Main Methods:
- 161 PTCP patients were divided into four groups based on oscillation parameters (1,500 rpm/1 min, 1,500 rpm/3 min, 3,000 rpm/1 min, 3,000 rpm/3 min).
- Platelet depolymerization rates were assessed pre- and post-oscillation using a hematology analyzer and special stain.
- Peripheral blood smears were examined for platelet distribution.
Main Results:
- Oscillation at 3,000 rpm significantly increased PLT counts compared to 1,500 rpm (p < 0.05).
- The highest depolymerization rate (93.79%) was achieved with 3,000 rpm for 3 minutes, significantly exceeding the special stain method (11.80%).
- Elevated lymphocyte count and potassium were risk factors for incomplete depolymerization; bilirubin levels were protective.
Conclusions:
- Oscillation at 3,000 rpm for 3 minutes is highly effective for platelet depolymerization in PTCP.
- Monitoring specific blood parameters can aid in the timely application of this oscillation method for accurate clinical detection.
More Related Videos
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
06:16Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
Published on: April 19, 2024
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.